S.VincentRajkumarMDFRCPC

PubMed

• Retreatment of multiple myeloma with previously refractory drugs.
  Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K Buadi
  Blood Advances. 2024-12-24
• Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database.
  S Vincent Rajkumar, María-Victoria Mateos, Marcy Schaeffer, Xiwu Lin, Sacheeta Bathija
  Blood Cancer Journal. 2024-12-05
• Prognostic Impact of Patient-Reported Symptoms in Multiple Myeloma.
  Nadine Abdallah, Arwa Bohra, Aytaj Mammadzadeh, Francis K Buadi, Prashant Kapoor
  Blood Advances. 2024-12-05

Journal Articles

• Impact of Prior Diagnosis of Monoclonal Gammopathy on Outcomes in Newly Diagnosed Multiple Myeloma  
  S Vincent Rajkumar, Yi L Hwa, Wilson I Gonsalves, Francis K Buadi, Angela Dispenzieri, Prashant Kapoor, Miriam A Hobbs, Martha Q Lacy, John A Lust, Robert A Kyle, Mori..., Nature
• Relapse After Complete Response in Newly Diagnosed Multiple Myeloma: Implications of Duration of Response and Patterns of Relapse  
  Angela Dispenzieri, Francis K Buadi, Morie A Gertz, Martha Q Lacy, Nelson Leung, Amie L Fonder, Wilson I Gonsalves, Yi Lisa Hwa, Taxiarchis Kourelis, Surbhi Sidana, Ro..., Nature
• Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia  
  Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
• Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy: Failure of the Serum Free Light Chain Ratio  
  Morie A Gertz, David Dingli, Miriam Hobbs, John A Lust, Ronald S Go, Amie Fonder, Yi Lin, Shaji K Kumar, Prashant Kapoor, Taxiarchis V Kourelis, S Vincent Rajkumar, Ro..., Nature
• Risk of MGUS in Relatives of Multiple Myeloma Cases by Clinical and Tumor Characteristics  
  Robert A Kyle, S Vincent Rajkumar, Alexandra J Greenberg, Abdul Rishi, Shaji Kumar, Nature
• Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...  
  John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
• Join now to see all

Books/Book Chapters

• Cecil Textbook of Medicine 
  Chapter: Plasma Cell Disorders 
  Rajkumar SVElsevierEdition 25th,2016
• Multiple Myeloma: Diagnosis and Treatment 
  Morie A. Gertz, S. Vincent Rajkumar (eds)Springer2013
• Abeloff's Clinical Oncology 
  Chapter: Multiple Myeloma and Related Disorders 
  S. Vincent RajkumarElsevierEdition 5th,2013
• Wintrobe's Clinical Hematology 
  Chapter: Monoclonal Gammopathies of Undetermined Significance and Smoldering Multiple Myeloma 
  S. Vincent Rajkumar, Robert A. Kyle, John A. LustWolters Kluvers/ Lippincott Williams & WilkinsEdition 13th,2013
• Amyloidosis: Diagnosis and Treatment 
  Morie A. Gertz, S. Vincent Rajkumar (eds)Humana Press2010
• Oxford Textbook of Medicine 
  Chapter: Myeloma and Paraproteinaemias 
  Robert A. Kyle, S. Vincent RajkumarOxford University Press2010
• Treatment of Multiple Myeloma and Related Disorders 
  S. Vincent Rajkumar, Robert A. Kyle (eds)Cambridge University Press2009
• Join now to see all

Abstracts/Posters

• Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
  Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Germline Variation Predicts Treatment Response in Multiple Myeloma
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Gene Expression Profiling of Structural and Functional High-Risk Multiple Myeloma
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Immunological Consequences of Lenalidomide with and without Dexamethasone in Newly Diagnosed Multiple Myeloma
  S.Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Association between a Polygenic Risk Score for Multiple Myeloma Risk and Overall Survival
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias
  S.Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH
  S.Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma
  S. Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome
  S.Vincent Rajkumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Approaches To Achieve the Best Possible Outcomes in Myeloma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Long-Term Survivorship with Active Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Longer Term Follow up of the  Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) w... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• New Strategies for Multiple Myeloma Care: Next Steps for The Future 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Debate: Value and Cost of Myeloma Therapy—We Cannot Afford It 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
• Join now to see all